Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear

2018-05-15 The new non-invasive test, using a blood sample of the pregnant woman, is as reliable as the conventional test using a blood sample of the newborn. Studies on benefit and harm are still lacking.

read more Link to \Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear\""

Osteoporosis: guidelines cover almost all important health care aspects

2018-05-08 The search update for a possible disease management programme “osteoporosis” showed that integrated concepts of medical and physical rehabilitation were hardly addressed.

read more Link to \Osteoporosis: guidelines cover almost all important health care aspects\""

Systematic treatment of periodontal disease: advantage of further therapeutic approaches

2018-04-30 An indication or hint of greater benefit was now shown for six instead of two therapeutic measures. This applies particularly to the attachment level.

read more Link to \Systematic treatment of periodontal disease: advantage of further therapeutic approaches\""

Suitable methods for evidence syntheses with very few studies

2018-04-27 If only 2 to 4 studies are available, meta-analyses often do not lead to informative results. However, suitable methods for evidence syntheses are available, even in the event of sparse evidence.

read more Link to \Suitable methods for evidence syntheses with very few studies\""

Fluoride varnish in the primary dentition can prevent caries

2018-04-26 Regular use of fluoride varnish can prevent caries in primary teeth. Advantages or disadvantages regarding further patient-relevant outcomes remain unclear due to a lack of data.

read more Link to \Fluoride varnish in the primary dentition can prevent caries\""

Coronary heart disease: DMP could be extended by two topics

2018-03-28 Almost all health care aspects need to be updated. The already third search update for guidelines shows that their number and quality have increased notably in 10 years.

read more Link to \Coronary heart disease: DMP could be extended by two topics\""

Dupilumab for neurodermatitis: indication of an added benefit in adults

2018-03-01 The first neurodermatitis drug undergoing the AMNOG procedure provides better symptom relief and has clear advantages particularly in the quality of life.

read more Link to \Dupilumab for neurodermatitis: indication of an added benefit in adults\""

Telemonitoring in cardiac disorders: benefit still unclear

2018-02-28 The data showed no relevant differences for some outcome criteria, and data were missing for others – also because some studies remain incompletely published.

read more Link to \Telemonitoring in cardiac disorders: benefit still unclear\""

Early benefit assessments: IQWiG completed 220th dossier assessment by the turn of the year

2018-01-18 A host of dossiers assessed by IQWiG to date have addressed oncology drugs. Despite their significance, other diseases, e.g. Alzheimer dementia, are underrepresented.

read more Link to \Early benefit assessments: IQWiG completed 220th dossier assessment by the turn of the year\""

Finding RCTs of new drugs: Searches in trial registries require specific adaptations

2018-01-05 IQWiG authors report on the availability of randomized controlled trials (RCTs) of newly approved drugs in trial registries as well as on specific search strategies.

read more Link to \Finding RCTs of new drugs: Searches in trial registries require specific adaptations\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
S16-05 Screening for depression on the preliminary report 2018-05-04
S16-03 Screening for hepatitis B on the preliminary report 2018-06-04
S16-04 Screening for hepatitis C on the preliminary report 2018-06-04

Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Fixed-dose combination of lumacaftor / ivacaftor (Orkambi) for the treatment of cystic fibrosis in children

The fixed-dose combination of lumacaftor / ivacaftor (trade name: Orkambi) has been approved in Germany since November 2015 in patients over the age of 12 years. Since February 2018, it has also been approved for children between the ages of 6 and 11 years.   read more (Link to \Fixed-dose combination of lumacaftor / ivacaftor (Orkambi) for the treatment of cystic fibrosis in children\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close